Evaluation of Two Chemiluminescent and Three ELISA Immunoassays for the Detection of SARS-CoV-2 IgG Antibodies: Implications for Disease Diagnosis and Patients’ Management
Ημερομηνία
2020Γλώσσα
en
Λέξη-κλειδί
Επιτομή
The estimation of anti-SARS-CoV-2 IgG antibodies is possibly the best approach to accurately establish the number of infected individuals and the seroprevalence of COVID-19 within a population. Thus, several commercial immunoassays have recently been developed. The purpose of our study was to assess the performance of five commonly used immunoassays in Greece (3 ELISA, namely Euroimmun SARS-CoV-2, GA GENERIC SARS-CoV-2 and Vircell COVID-19; and 2 chemiluminescent, namely ABBOTT SARS-CoV-2 and ROCHE Elecsys Anti-SARS-CoV-2 test) for the detection of anti-SARS-CoV-2 IgG antibodies. Sera specimens derived from 168 individuals were utilized to assess the specificity and sensitivity score of each assay. Among them, we included 99 COVID-19 patients (29 asymptomatic, 36 with symptom onset 4 to 14 days before serum sampling, and 34 with symptom initiation ≥ 15 days ago), and 69 volunteers with sera specimens collected prior to the SARS-CoV-2 outbreak and maintained at −80°C. We demonstrated that chemiluminescent immunoassays exhibit a significantly higher specificity score but a lower sensitivity, compared to ELISA immunoassays. Moreover, immunoassays detecting IgG antibodies against SARS-CoV-2 N protein instead of S protein alone are more reliable, considering both specificity and sensitivity scores. Interestingly, all asymptomatic patients displayed anti-SARS-CoV-2 IgG antibodies, confirmed by at least two immunoassays. We suggest that chemiluminescent assays could be used as screening methods for the detection of anti-SARS-CoV-2 antibodies to evaluate the possible prevalence of disease in the general population, while ELISA assays would be more reliable to evaluate, and follow-up confirmed COVID-19 patients. © Copyright © 2020 Speletas, Kyritsi, Vontas, Theodoridou, Chrysanthidis, Hatzianastasiou, Petinaki and Hadjichristodoulou.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies
Pavlidis P., Komorowski L., Teegen B., Liaskos C., Koutsoumpas A.L., Smyk D.S., Perricone C., Mytilinaiou M.G., Stocker W., Forbes A., Bogdanos D.P. (2016)Background: Pancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn's disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of ... -
(2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease
Manolakis A.C., Christodoulidis G., Kapsoritakis A.N., Georgoulias P., Tiaka E.K., Oikonomou K., Valotassiou V.J., Potamianos S.P. (2017)AIM: To investigate the impact of inflammatory bowel disease (IBD) on α2-Heremans-Schmid Glycoprotein (AHSG/fetuin A) and potential associations with disease and patient characteristics. METHODS: AHSG serum levels were ... -
Do the Kinetics of Antibody Responses Predict Clinical Outcome in Hospitalized Patients With Moderate-to-Severe COVID-19?
Pavlidis G., Kampolis C.F., Perlepe G., Pagonis A., Maniotis C., Koullias E., Kranidioti H., Kyritsis A., Pavlou E., Sinis S., Pirounaki M., Vassilopoulos D., Gourgoulianis K., Pantazopoulos I. (2022)Background/Aim: The relationship between the kinetics of antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the severity of Coronavirus Disease 2019 (COVID-19) is poorly understood. The ...